1 / 41

Chronic Myelogenous Leukemia (CML)

Chronic Myelogenous Leukemia (CML). Faculty. Chronic Myelogenous Leukemia. Chronic Myelogenous Leukemia. Etiology. Epidemiology of CML in the US. The Role of BCR-ABL in CML. The Role of BCR-ABL in CML. Uncertainties Related to BCR-ABL. Mechanism of Action of Imatinib Mesylate.

orly
Download Presentation

Chronic Myelogenous Leukemia (CML)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Chronic Myelogenous Leukemia (CML)

  2. Faculty

  3. Chronic Myelogenous Leukemia

  4. Chronic Myelogenous Leukemia

  5. Etiology

  6. Epidemiology of CML in the US

  7. The Role of BCR-ABL in CML

  8. The Role of BCR-ABL in CML

  9. Uncertainties Related to BCR-ABL

  10. Mechanism of Action of Imatinib Mesylate

  11. Imatinib as Initial Treatment

  12. Cumulative Best Response at 12 and 60 Months on First-Line Imatinib

  13. Event-Free Survival and Survival Without AP / BC on First-Line Imatinib 60 Months

  14. Overall Survival on First-Line Imatinib (ITT Principle) at 60 Months

  15. Monitoring Extent of Disease

  16. NCCN Indications for Cytogenetic Testing and BCR-ABL mRNA PCR

  17. NCCN Indications for Cytogenetic Testing and BCR-ABL mRNA PCR

  18. NCCN Criteria of Response to Treatment

  19. Definition of Molecular Response to Treatment

  20. Degree of Cytogenetic & Molecular Response at 12 or 18 Months Associated With Long-Term Freedom from Progression

  21. Early Prediction of Treatment Outcomes

  22. Current Clinical Predictors at Diagnosis

  23. Predictors of Imatinib Response

  24. Potential Mediators of Imatinib Responsiveness & Resistance

  25. Mutations Within Kinase Domain (KD) of BCR-ABL

  26. Mutations Within Kinase Domain of BCR-ABL That Impart Clinical Resistance to Specific TKIs

  27. T315I Mutation May Not ImpartWorse Prognosis Than Other Mutations

  28. Drug Transport Variability:Human Organic Cation Transporter

  29. Trough Imatinib Concentrations

  30. Approaches to Imatinib Resistance

  31. Dasatinib

  32. Dasatinib in Chronic Phase CML Resistant to First-Line Imatinib

  33. Dasatinib in Chronic Phase CML Resistant to Imatinib15-Month Follow-Up Results

  34. Dasatinib in Chronic Phase CML Resistant to Imatinib15-Month Follow-Up: Time to Treatment Failure

  35. Nilotinib

  36. Nilotinib: Open Label Phase II Study in Chronic Phase CML Patients Resistant to or Intolerant of Imatinib6-Month Follow-Up of 280 Patients

  37. Investigational Agents in Clinical Trials

  38. NCCN Guidelines

  39. Summary

  40. Summary

More Related